|
Promotieonderzoek:
Urologisch Research Laboratorium, afdeling Urologie, Universitair Medisch Centrum St. Radboud, Nijmegen.
Promotoren: Prof. dr. F.M.J. Debruyne en Prof. dr. J.A. Schalken.
Copromotoren: Prof. dr. J.A. Witjes en Prof. dr. L.A.L.M. Kiemeney.
Onderwerp: New aspects in diagnosis and prognosis of superficial bladder cancer.
J.L.J. Vriesema, H.G. van der Poel, F.M.J. Debruyne, J.A. Schalken, L.P. Kok, M.E. Boon: Neural network-based digitized cell image diagnosis of bladder wash cytology. Diagnostic Cytopathology 2000;23:171-179. Abstract.
N.A. Mungan, J.L.J. Vriesema, C.M.G. Thomas, L.A.L.M. Kiemeney, J.A. Witjes: Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer. Urology 2000;56:787-792. Abstract.
J.L.J. Vriesema, M.H. Poucki, L.A.L.M. Kiemeney, J.A. Witjes: Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis. Urology 2000;56:793-797. Abstract.
J.L.J. Vriesema, K.K. Aben, J.A. Witjes, L.A.L.M. Kiemeney, J.A. Schalken: Superficial and metachronous invasive bladder carcinomas are clonally related. Int J Cancer 2001;93:699-702. De gehele publicatie.
J.L.J. Vriesema, F. Atsma, L.A.L.M. Kiemeney, W.P. Peelen, J.A. Witjes: Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 2001;58:367-371. Abstract.
J.A. Witjes, J.L.J. Vriesema, A.G. van der Heijden, G.J. Peters, J.A. Schalken: Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs. Eur Urol 2003;44:615-619. De gehele publicatie.
J.A. Witjes, J.L.J. Vriesema, K. Brinkman, G. Bootsma, J.O. Barentsz: Mycotic aneurysm of the popliteal artery as a complication of intravesical BCG therapy for superficial bladder cancer. Case report and literature review. Urol Int 2003;71:430-432. Abstract.
J.A. Witjes, A.G. van der Heijden, J.L.J. Vriesema, G.J. Peters, A. Laan, J.A. Schalken: Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 2004;45:182-186. De gehele publicatie.
J.L.J. Vriesema: Tumormarkers bij (oppervlakkig) blaascarcinoom; klinische aspecten. Ned Tijdschr Klin Chem Labgeneesk 2005;30:5-6.
De gehele publicatie.
J.P. Heesakkers, J.L.J. Vriesema: The role of urodynamics in the treatment of lower urinary tract symptoms in women. Curr Opin Urol 2005;15:215-221. Abstract.
B.P.H. Schrier, J.L.J. Vriesema, J.A. Witjes, L.A.L.M Kiemeny, J.A. Schalken: The predictive value of p53, p27(Kip1), and alpha-catenin for progression in superficial bladder carcinoma. Eur Urol 2006;50:76-82. De gehele publicatie.
J.L.J. Vriesema, J.A. Witjes, F.M.J. Debruyne, J.A. Schalken: Value of analyzing p53 status, or other objective markers, when determining management strategies. Chapter 21. Pathology of the urinary bladder. 2004.
P.N. Span, J.A. Witjes, N. Grebenchtchikov, A. Geurts-Moespot, P.M. Moonen, T.W. Aalders, J.L. Vriesema, L.A. Kiemeney, J.A. Schalken, F.C. Sweep: Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. BJU Int 2008;102:177-182. De gehele publicatie.
|
